Onapsis Partners with Microsoft to Boost Enterprise Defense with End-to-End SAP Security Monitoring

.406 Venture

Onapsis Defend integration with Microsoft Sentinel Solution for SAP helps Security Operations teams strengthen SAP threat detection and response

 

BOSTON, MA., September 30, 2025 – Onapsis, a global leader in SAP cybersecurity and compliance, today announced the launch of a new integration between its flagship Onapsis Defend threat monitoring product and Microsoft Sentinel Solution for SAP, based on Microsoft’s AI-powered cloud-native Security Information and Event Management (SIEM) platform. The integration provides security operations centers (SOC) with unified visibility and threat detection and response capabilities for SAP security events.

SOC teams struggle with a profound visibility gap into activity happening in their mission-critical SAP landscapes, which commonly serve as foundational systems of record for enterprises. This gap includes identifying SAP threats, detecting SAP-targeted exploits and zero-day activity, suspicious user or insider behavior, sensitive data downloads, security control violations and more. The new integration provides organizations with a superior early warning system with proprietary exploit detection rules for business-critical SAP applications, enabling their security teams to detect exploit attacks on vulnerable SAP systems before patches are even released.

“The collaboration extends the power of Onapsis’ SAP-endorsed, industry-leading threat monitoring directly into Microsoft Sentinel Solution for SAP,” said Sadik Al-Abdulla, Onapsis Chief Product Officer. “By unifying Onapsis’ context-rich insights with Microsoft Sentinel’s Solution for SAP, enterprises can investigate and respond to SAP threats faster, meet strict disclosure requirements with confidence and strengthen their security posture across both on-prem, cloud and RISE with SAP environments.”

Key benefits of the integration include:

  • Specialized Exploit and Zero-Day Detection: The Microsoft Sentinel Solution for SAP offers advanced pre-patch exploit protection and early warning alerts against cyberattacks, enriched with threat intelligence from Onapsis Research Labs and their Global SAP Threat Intelligence Network. This collaboration enhances Microsoft Sentinel’s native SAP capabilities with specialized insights from one of the industry’s most trusted research teams.
  • Context-Rich Alerts, Designed for the SOC: SAP events are uniquely enriched with detailed explanations, mitigation guidance, and anomaly scoring from the SAP cybersecurity experts at the Onapsis Research Labs to accelerate investigations
  • AI-Powered Security Insights: The powerful Microsoft Sentinel Solution for SAP and Microsoft Security Copilot AI capabilities, combined with the security insights and threat intelligence from Onapsis, offer superior identification of sophisticated attacks affecting your SAP and broader environment.
  • Unified Security Operations: With market-leading SAP threat and exploit detection from Onapsis, organizations can push security events to Microsoft Sentinel Solution for SAP for correlation with broader enterprise events to streamline incident handling and reduce response times through a unified view of the overall threat landscape in the Microsoft Unified SecOps Platform.

“Microsoft takes a holistic approach to SAP security, moving beyond isolated conversations. By integrating threat intelligence across the enterprise, and Security Copilot into Microsoft Defender Portal, we demonstrate that security isn’t limited to SAP Applications or data – it is about the whole ecosystem,” said Martin Pankraz, Product Manager, SAP Security, Microsoft. “Onapsis complements that effort with their market-leading pre-breach capabilities such as SAP exploit and zero-day detection, SAP Vulnerability Management or ABAP Code Security. We’re delivering deeper protection for our customers’ SAP landscapes, empowering them to respond to SAP threats faster and keeping them far ahead of the latest SAP attacks and exploitation techniques from malicious threat actors.”

It has been a watershed year for defenders marked by a series of high-profile SAP vulnerabilities, zero-days and global attack campaigns that led to hundreds of enterprises being compromised. Despite SAP’s rapid patching, security practitioners are still faced with the ongoing challenge of protecting their business-critical applications in a sophisticated threat landscape. Considering the notable success of well-funded threat actor groups targeting SAP applications, directly combined with significantly stricter regulatory requirements under EU NIS2 and SEC rules in the US, and the looming deadline for migration to SAP S/4HANA through RISE with SAP, organizations find themselves under unprecedented pressure to better secure their SAP landscapes. The Onapsis integration with Microsoft Sentinel Solution for SAP directly addresses these challenges by giving SOC teams the visibility and control needed to rapidly respond to an increasing number of threats to critical SAP systems.

Availability

The Onapsis Defend for Microsoft Sentinel Solution for SAP integration is available today. Pricing and further details available through Onapsis sales representatives or authorized systems integrators. For more information, please visit the Microsoft Azure Marketplace.

About Onapsis

Onapsis is the global leader in SAP cybersecurity and compliance, trusted by the world’s leading organizations to securely accelerate their SAP cloud digital transformations with confidence. As the SAP-endorsed and most widely used solution to protect SAP, the Onapsis Platform empowers Cybersecurity and SAP teams with automated compliance, vulnerability management, threat detection, and secure development for their RISE with SAP, S/4HANA Cloud and hybrid SAP applications. Powered by threat insights from the Onapsis Research Labs, the world’s leading SAP cybersecurity experts, Onapsis provides unparalleled protection, ease of use, and rapid time to value, empowering SAP customers to innovate faster and securely. Connect with Onapsis on LinkedInX, or visit https://www.onapsis.com.

Categories: News

Tags:

Emerald backs FREDsense in $7M Series A to speed up PFAS field testing

Emerald

Calgary, Canada — Emerald has announced its participation in FREDsense’s USD $7 million Series A funding round, led by HG Ventures. FREDsense delivers practical, next-generation solutions for detecting PFAS —“forever chemicals”— by providing fast, portable testing equipment that allows customers to get results in hours rather than weeks.

The company has launched the first commercially available field-based PFAS detector and has seen early adoption across industries such as environmental consulting & services, water and wastewater treatment, energy and general industrial operations. By replacing lengthy lab turnaround times with same-day answers onsite, FREDsense enables onsite teams to identify contamination hotspots, verify cleanups, and optimize treatment more efficiently and at lower cost.

“FREDsense is bringing much-needed speed and practicality to PFAS testing,” said Clayton MacDougald, Investment Director at Emerald and newly appointed FREDsense Board Member. “When you can get reliable results the same day, you make better decisions, finish jobs faster, and reduce costs. We’re thrilled to back this team alongside HG Ventures.”

“Communities and companies need cleaner water, faster answers, and fewer delays,” said Ginger Rothrock, Senior Director at HG Ventures. “FREDsense puts lab-level insight into the hands of field teams, which is exactly what this moment requires. We’re proud to lead the round and support FREDsense as they scale.”

“Our mission is simple: make PFAS testing fast, accessible, and actionable,” said David Lloyd, CEO of FREDsense. “With support from HG Ventures and Emerald, we’ll expand production, deepen customer support, and continue improving our product so more sites can get answers on the spot.”

Looking ahead

FREDsense is building toward long-term relevance in a market of extreme importance, where PFAS sits at the intersection of environmental urgency, human health concerns, regulatory enforcement and economic opportunity within a  global multi-billion-dollar problem. With its first-mover advantage, growing commercial traction, and scalable business model, FREDsense represents a compelling opportunity for players in the PFAS space that are seeking differentiated tools to strengthen their portfolios and respond to regulatory and customer demand.

Categories: News

Tags:

Onapsis Unveils New Platform Updates Delivering the Deepest Level of SAP Application Security Posture Insights to Date

.406 Venture

The company launches SAP Notes Command Center, Rapid Controls and expands its SAP BTP coverage and Onapsis Security Advisor capabilities to protect SAP applications   

 

BOSTON, MA – September 25, 2025Onapsis, the global leader in SAP cybersecurity and compliance, today announced major updates to its Onapsis Platform, including the launch of three new capabilities – the SAP Notes Command Center, Rapid Controls for Dangerous Exploits, and Alert on Anything for SAP Business Technology Platform (BTP). Together, these enhancements arm organizations with deeper insights, greater visibility, and new automation to strengthen their SAP application security posture.

“This is a pivotal time in SAP security. Organizations no longer have the time to spend sorting through false positives or wondering if a patch is applied correctly; instead, they need security solutions that are customizable to their business and attack surface,” said Mariano Nunez, CEO of Onapsis. “The new capabilities in our Assess and Defend products, as well as the expansion of our platform, provide our customers with the technologies they need to keep ahead of sophisticated threat actors, protect their most valuable data, and achieve business resilience.”

The exploitation of SAP applications is a top concern for organizations, as this year the industry is experiencing a record number of attacks targeting business-critical applications, leaving thousands of enterprises compromised. To help ensure companies are prepared and protected, Onapsis is delivering new updates that proactively discover threat activity with enhanced exploit detection rules and streamline all SAP security measures with task prioritization and patch validation. These updates include:

  • SAP Notes Command Center in Assess: Empowers users to easily anticipate SAP patch days and prioritize tasks while also providing additional insights into SAP Note applications. This new dashboard eliminates the time spent on false positives, reduces the risk of undetected vulnerabilities and automatically validates that all patches – including manual configurations and workarounds – were applied correctly
  • Rapid Controls: Leverages Defend’s unique exploit detection rules to monitor for threat activity targeting the most dangerous SAP vulnerabilities. These controls proactively address the risk of critical vulnerabilities and support regulatory requirements, such as EU NIS2 and US SEC rules
  • Alert on Anything for SAP BTP: Enables organizations to customize and expand their BTP threat monitoring, providing users with the flexibility needed to manage security controls tailored to individual use cases
  • Expanded Coverage Analysis in Onapsis Security Advisor: Automatically identifies assets in a customer’s security landscape that are not being actively monitored for threats, expanding their visibility to detect and act on any potential unmonitored critical systems in their SAP business landscapes

“Onapsis’ unique insights and unmatched data set put us at the forefront of application security,” said Sadik Al-Abdulla, Chief Product Officer at Onapsis. “With the launch of these new enhancements, organizations are able to take control of their SAP security by proactively addressing any vulnerabilities and automatically identifying assets that aren’t protected in their security landscape but could weaken or cause disruption to their SAP applications.”

Availability

These new enhancements will be available in late September 2025. Pricing and further details are available through Onapsis sales representatives or authorized systems integrators. For more information, please visit: https://onapsis.com/platform/

About Onapsis

Onapsis is the global leader in SAP cybersecurity and compliance, trusted by the world’s leading organizations to securely accelerate their SAP cloud digital transformations with confidence. As the SAP-endorsed and most widely used solution to protect SAP, the Onapsis Platform empowers Cybersecurity and SAP teams with automated compliance, vulnerability management, threat detection, and secure development for their RISE with SAP, S/4HANA Cloud and hybrid SAP applications. Powered by threat insights from the Onapsis Research Labs, the world’s leading SAP cybersecurity experts, Onapsis provides unparalleled protection, ease of use, and rapid time to value, empowering SAP customers to innovate faster and securely. Connect with Onapsis on LinkedInX, or visit https://www.onapsis.com.

Categories: News

Tags:

Announcing our investment in Inspiren

Scale Venture Partners

Scale is excited to announce our investment in Inspiren’s $100M Series B!

By 2030, 1 in 5 Americans will be aged 65 or older, and without technology senior living communities won’t be able to safely keep up with demand. Inspiren is creating a safer future for older adults by helping senior living communities deliver safer, higher quality care through unifying resident safety, care planning, staffing, and emergency response into a single, AI-powered platform.

Today, senior living care teams are flying blind on critical details of patient care and rely on inaccurate care plans, midnight rounding, and some of the worst software you’ve ever seen to deliver care to incredibly vulnerable patient populations. Inspiren replaces guesswork with data by combining hardware and software to give care teams a real-time view of resident behavior they can use for both tactical care delivery and long-term planning. The end result? Safe residents, happy staff members, and financially prosperous senior living communities.

Inspiren is a case study in category creation and how impeccable execution can shift industry sentiment in a matter of months. We were first introduced to the business last fall and were immediately impressed with Alex and the value Inspiren was delivering to its early adopters. However, industry sentiment at large was mixed. Theoretical ROI was easy to grok, but operators burned by past generations of technology over-promising and under-delivering had concerns about product quality and resident privacy. Fast forward eight months and industry sentiment had totally flipped: Inspiren is the obviously better way to run a senior living community.

So what changed and convinced operators that Inspiren should be the new standard of care? At the core of Inspiren’s success is privacy-first design driven by tight coupling between hardware and software. When a community adopts Inspiren, sensors are installed in resident’s rooms that monitor activity and alert nurses when residents might be in trouble. To be clear, these aren’t security cameras: they’re beautiful, unobtrusive devices that leverage audio, visual, and radar inputs to create a privacy-preserving digital twin of every resident. Care teams get exactly the right amount of information to help residents when they need it and residents don’t feel like they’re living under a surveillance state.

Informed care teams are effective care teams and Inspiren’s data helps create safer communities. This is particularly important when resident needs change rapidly. When residents join a community, there’s an initial medical evaluation that determines a care plan based on their needs. However, resident health can change meaningfully in a matter of weeks. In the current state, care teams will recognize that and start ad-hoc delivering more care, but without a formal re-evaluation the care plan won’t be rigorous, and the community won’t be compensated for the increased care levels. Inspiren changes that. Data from Inspiren’s sensors is fed back into their software platform and will proactively flag residents who might need increased care. Inspiren’s clinical team reviews that data with communities and together they make sure that all residents are getting the care they need with financial arrangements that make sense for the community. The results are stunning: Inspiren customers are seeing 80%+ reductions in bedroom-related falls with an injury.

Inspiren is the latest of many bundled sensors and software deals in our portfolio and joins the likes of Motive, Locus Robotics, Spot AI, VergeSense, and others injecting intelligence into real-world operations. A hard-earned learning of ours is that it’s incredibly difficult to build a sensor + software platform that delivers hard ROI to customers at a price point that makes the unit economics work for the business. Alex, Michael, and the rest of the Inspiren team have done exactly that and are helping some of the largest senior living communities better serve thousands of residents and their families. We’re honored to be a part of their mission.

New York Cancer & Blood Specialists (NYCBS) Partners with OncoveryCare to Launch Cancer Survivorship Care

.406 Venture

OncoveryCare’s survivorship-trained clinicians will treat the chronic and late-effects of cancer treatment to help bring comprehensive care to New York Cancer & Blood Specialists’ cancer survivor population.

 

RIDGE, NY / ACCESS Newswire / September 24, 2025 / New York Cancer & Blood Specialists (NYCBS), one of the nation’s leading community oncology practices, today announced a partnership with OncoveryCare to provide personalized, ongoing care to the NYCBS survivor population. Beginning today, OncoveryCare will work alongside NYCBS oncologists to treat the chronic and late effects of cancer treatment and provide comprehensive cancer follow-up care for NYCBS patients.

As cancer diagnoses increase and mortality rates fall with improvements in treatment, survivorship has become one of cancer care’s most urgent priorities. By 2040, the number of cancer survivors in the United States is expected to reach 26 million – up from 18 million in 2022. At the same time, cancer is increasingly diagnosed at younger ages, leaving survivors to manage its effects for decades. Survivorship care addresses the full spectrum of needs beyond treatment – including managing treatment toxicities, chronic co-morbidities, and mental health. Integrating survivorship into oncology ensures patients receive continuous, comprehensive care.

Through this collaboration, OncoveryCare will deliver comprehensive survivorship care, including integrated medical and behavioral healthcare, to help cancer survivors fully engage in life after cancer. OncoveryCare’s clinical team comprises survivorship-trained Advanced Practice Providers and Licensed Clinical Social Workers with extensive experience in medical oncology, who treat survivorship-related conditions such as fatigue, joint pain, sexual dysfunction, insomnia, anxiety, and more. OncoveryCare clinicians are integrated as part of the broader oncology team – working in close collaboration with the patient’s existing care team.

Dr. Jeff Vacirca, CEO of NYCBS and Co-founder of OneOncology, said “Cancer survivorship is one of the most important frontiers in oncology. Our partnership with OncoveryCare ensures that our patients don’t just survive cancer, but truly thrive in life after treatment. Together, we are setting a new standard for comprehensive survivorship care that addresses every aspect of a patient’s well-being.”

“Cancer doesn’t end when treatment does, and neither should care,” said Dr. MaryAnn Fragola, Chief of Wellness Services at NYCBS. “Through our partnership with OncoveryCare, we are strengthening our commitment to whole-person, patient-centered care by addressing the long-term medical, emotional, and on-going needs of survivors and their loved ones.”

Hil Moss, Co-Founder and CEO of OncoveryCare, said “New York Cancer & Blood Specialists is an innovative leader in oncology, and we’re thrilled to launch a partnership that will transform care for survivors in New York.” Dr. Justin Grischkan, Co-Founder and Chief Medical Officer at OncoveryCare, added, “We are inspired by NYCBS’s commitment to providing comprehensive survivorship care to their patients.”

About New York Cancer & Blood Specialists

New York Cancer & Blood Specialists is a leading oncology practice dedicated to providing world class, patient-centered, and affordable care to individuals with cancer and blood disorders throughout New York State. With locations across Long Island, New York City, and Upstate New York, our mission is to bring world-class cancer care close to home, where patients can heal with the support of family and community.

About OncoveryCare

OncoveryCare delivers comprehensive, whole-person care to cancer survivors. As the population of survivors grows rapidly alongside advances in medicine, OncoveryCare provides the personalized, longitudinal care that cancer survivors need to lead happier, healthier lives. Founded by a breast cancer survivor and a physician, OncoveryCare deploys a survivorship-trained clinical team to treat the chronic and late-effects of each survivor’s cancer treatment and equip survivors with the tools they need to manage their survivorship journey.

OncoveryCare is backed by leading investors and oncology stakeholders, including .406 Ventures, Tennessee Oncology’s McKay Institute, F-Prime, and Oncology Ventures. Learn more at www.oncoverycare.com, and follow us on LinkedIn and Instagram @oncoverycare.

Media Contact
Chloe Baldwin
Senior Manager, Community & Marketing
chloe@oncoverycare.com

Categories: News

Tags:

Scindo raises $5.4m seed round for AI-powered enzyme discovery platform

Agfund

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in  Scindo]

  • Scindo—a UK-based startup building an AI-powered enzyme discovery and design platform—has raised a £4 million ($5.4 million) seed round.
  • The round was co-led by Kadmos Capital and Clay Capital, with participation from PINC, the venture arm of food and beverage company Paulig, and existing investors SynbiovenAgFunderSOSVFarvatn Venture and Savantus Ventures.
  • Scindo develops enzymes—nature’s tiny biological catalysts—that can transform a wide range of feedstocks into ingredients that have historically been sourced from petrochemicals.

Founded in 2020 by Dr. Gustaf Hemberg, Dr. Ben Davis, and Juliet Sword, Scindo combines AI models with proprietary data to accelerate enzyme discovery and optimization.

The firm, which has established partnerships with leading specialty chemical manufacturers, develops enzymes for several industry verticals including food and flavorings, cosmetics, and specialty chemicals.

With the new funding, it will expand its platform, scale wet-lab capabilities and strengthen its team.

“The specialty chemicals industry has long sought to move away from petrochemical-derived ingredients, but existing approaches have struggled with complex natural feedstocks,” said Ali Morrow, partner at lead investor Clay Capital.

“Scindo’s approach creates molecular craftsmen: enzymes designed for specific industrial jobs that offer cost-competitive natural alternatives and unlock previously inaccessible feedstocks, creating significant opportunities globally to end the industry’s reliance on crude oil.”

Designer enzymes

Scindo CEO Gustaf Hemberg told AgFunderNews: “When we started, we focused on mapping enzymes with functionalities that are difficult to achieve selectively with traditional chemistry and relatively uncommon in nature—particularly C–H activations and C–C bond cleavages [thereby opening up route for degrading stubborn molecules such as plastics].”

“By discovering and characterizing these underexplored enzymes, we built datasets that could be fed into our machine learning models—not only to identify new enzymes with previously unknown functionalities, but also to enable generative design of novel enzymes with entirely new capabilities.

“That’s really at the core of what we do: by gathering new examples and generating proprietary datasets of enzymes with novel and defined functionalities and selectivities, we enable our machine learning models to learn which parts of the sequence or structure drive the performance or selectivity that we’re targeting.

“And that’s the real challenge with public datasets—they’re concentrated on a few well-studied enzyme families with narrow, specific functionalities. They’re often incomplete and sometimes even contain mischaracterized examples, which makes them limiting when training models for prediction or generative design of enzymes for novel transformations and the specific applications that we are targeting.”

Once Scindo has identified suitable candidates, it engineers these enzymes further—first to optimize selectivity and transformation efficiency, and then to improve physical traits such as thermostability and expressibility, said Hemberg. Scindo also collects and enriches its predictive models with rich metadata to identify candidates most likely to scale in industrial settings and express at high yields in microbial systems. This ensures maximum viability for rapid scale-up and collaboration with manufacturing partners, he explained.

“We have quite a big chemistry screening platform, so we are able to test the enzymes in the lab, characterize them and then feed that data back into the machine learning. Closing the loop between real life results and machine learning has been really critical for us.”

Once it has tested some candidates, it can do further work to rank them based on viability for scaling up in a microbial expression system and then work with an enzyme manufacturer to scale up production, said Hemberg.

Cell-free biomanufacturing

Scindo’s first two products are enzymes that can create key building blocks of flavors & fragrances, and enzymes that can enable cost-effective petrochemical-free production of a high-value cosmetic ingredient via cell-free biomanufacturing.

In the case of flavor and fragrance ingredients, he said, “We can use a wide range of agricultural fatty acid feedstocks and have designed enzyme systems that selectively convert them into flavor molecules. We’re now advancing into pilot-scale production through a partnership we haven’t yet announced.

“Some of those flavor ingredients could be produced with precision fermentation [by engineering microbes to express them in costly steel fermentation tanks], but that is much more expensive [than using a cell-free approach just using enzymes], the titers are quite low, and you generate a lot of waste metabolites.”

By using a cell-free approach that utilizes the internal machinery of microbial cells (such as enzymes) to convert feedstocks into the target flavor molecules, Scindo can significantly reduce production costs, he claimed.

Operating outside the constraints of a cell—and without relying on costly cellular cofactors—allows Scindo to run faster reactions across a wider range of conditions, such as pH and temperature, and in ways that significantly reduce energy consumption as there is less heating and cooling required, he explained. It also generates cleaner products that require less costly downstream processing.

“We’re hoping to target a market launch in the next 12 months or so for our first two products.”

Proprietary data sets

Stepping back, he said, the world’s largest enzyme companies tend to concentrate on a few specific enzyme families for traditional applications, particularly in food, laundry detergents, and some pharma applications.

“We are instead focusing on novel applications that have historically been much more difficult to target with traditional chemistry and enzymes alike.

“Our key differentiator is the proprietary data we’ve built around novel enzymes—their functionalities, specificities, and characteristics—with broad applicability to carbon-chain transformations. That’s really what separates us: we’re working with data that isn’t publicly available.”

Prosper AI: Turning Hold Music into Healthcare Access

Emergence

A few months ago, a close family member of mine needed a routine medical procedure. The care team was ready. The facility had an opening. But the entire process was put on hold while the office staff chased down a prior authorization from the insurance company. Days of back-and-forth. Hours of staff time. And in the meantime, unnecessary anxiety for my family.

Unfortunately, this is not an unusual story. It’s the reality of a system where a third of the healthcare workforce is dedicated to administrative tasks, costing over $450 billion annually. Endless phone calls, long hold times, and redundant processes eat up resources that should be directed toward patients.

That’s why we’re so excited about Prosper AI, which today announced a $5 million Seed round to bring voice AI agents purpose-built for healthcare to market. Emergence is proud to lead the round, alongside Y Combinator, CRV, and Company Ventures.

Prosper is working with industry leaders like a 30,000-employee billing company to transform their core operations. In speaking to customers, we consistently heard that voice AI is the biggest innovation in the healthcare revenue cycle management area since the EHR, and that Prosper’s product was the best in market. This customer love is driving rapid growth, as Prosper has more than quadrupled revenue since last quarter.

Prosper co-founders Xavier de Gracia and Josep Mingot met in Boston while studying at MIT and Harvard, and their backgrounds in call centers and regulated industries uniquely positioned them to build AI agents for healthcare’s most complex workflows.

When I think back to that delayed procedure, I can’t help but wonder how different the experience could have been if Prosper’s agents were already deployed. Faster authorizations. Less stress. More care delivered on time.

Healthcare should be about patients, not paperwork. That’s the future Prosper AI is building—and why we’re so proud to partner with them on the journey.

French startup NxtFood (ACCRO) raises $58m to scale alt-meat platform, aims for profitability in 12-18 months

Agfund

While sales of plant-based meat are going backwards in many markets, French startup Nxtfood—best known for the ACCRO brand—has just secured a €49 million ($58 million) funding round on the back of rapid growth in retail and foodservice markets.

The round was backed by existing investors Creadev and Roquette Ventures, and new investors Clay Capital and IRD Invest (Groupe IRD).

The investment is Singapore-based Clay Capital’s first in plant-based meat alternatives, said managing partner Matthieu Vermersch. “We have long observed the plant-based meat market with caution, looking for the right alignment between product, strategy, and team. With Nxtfood, we have found a company that combines operational excellence at scale, European ambition, and a clear path to profitability – a challenge that few players in this sector are able to meet today.”

The capital will be used to expand production at Nxtfood’s site in Vitry-en-Artois, France, tripling its footprint to 12,000 square meters, and fund further R&D in high moisture extrusion.

It will also be used to accelerate sales and marketing in France via the ACCRO brand, and elsewhere in Europe via b2b and co-manufacturing opportunities, says the firm, which aims to achieve profitability in 12-18 months.

ACCRO products. Image credit: Nxtfood
Image credit: Nxtfood

Rapid growth

Founded in 2019 and with its first products into the foodservice market in late 2022, Nxtfood develops plant-based meat products from locally grown wheat and pea proteins. It claims to be the fastest-growing plant-based start-up in France, with 20+ products spanning alt chicken, beef and pork sold in all leading food retailers and 10,000+ foodservice outlets.

CEO Renaud Saïsset told AgFunderNews: “In 2022 we did €1 million ($1.2 million), last year we were at €9.2million ($10.8 million), and this year, we will finish the year at around €17.4 million ($20.5 million). So that’s a nice growth, but there’s still a lot to do.”

Reaching profitability is in part a function of economies of scale, said Saïsset. “With our new industrial plan, we will also improve efficiency and yield so we will improve our production margin, but we are also careful on controlling spending.”

The French alt meat market

While sales of meat alternatives are flat or down in many markets, the French market is growing at a double-digit rate, he claimed. “Retailers and foodservice companies want to catch the major part of this growth, so they are dedicating more space to these products and welcoming innovations, provided that they offer something new.

“Most of them have launched private labels, a key growth opportunity for us [as a co-manufacturer] … and they are investing in terms of advertising and promotions. The private label share of market is increasing very fast, so they are very excited about this category.”

On merchandising, he said, “There are still lots of questions to understand where would be the best place to put these products [in the store]. At the moment, most are gathered in the chilled prepared food area, and this seems to work. But they are thinking of other possibilities, so there are some tests to try to see what could be the best implementation in the future.”

In foodservice, meanwhile, “We are targeting all parts of the market,” said Saïsset. “QSR and commercial channels are working very well and it’s a good way of opening the market, because consumers are happy to try things [when they eat out] and discover this new generation of products. And then they are more eager to buy them in retail.

“There is also a strong opportunity in school canteens because there is experimentation in France to bring more plant-based menus. And this new generation of products is much more attractive because they don’t have so much waste. Before, with the plant-based menu that they proposed, they had a lot of waste, but now, the level of waste is the same as [conventional] meat.”

The trough of disillusionment  

Asked about the funding landscape, Saïsset said: “The global economic context is tougher than before, for sure. And I think investors have also been disillusioned about the plant-based market as expectations were too high. I think all the signs are good, but it takes time to change habits.”

In France, he said, the plant-based market “is a bit younger and less mature and if we are clever, we should learn from what happened in some other markets. We have to focus on bringing more innovation, not just more brands. I could see in the UK market some years ago for example that there were lots of brands, but they were all making the same products.”

While it’s only one factor, he said, consumers also want shorter ingredients list, balanced nutrition, and clean labels in the meat alternatives market.

“We have a very short ingredient list and a very clean product. We only have green [colors] in [front-of-pack nutrition labeling scheme] Nutri-Score and we are also very careful to bring the right level of proteins at the same level as meat, plus we are rich in fibers and low in saturated fat.”

The Nxtfood (ACCRO) team. Image credit Nxtfood
Image credit Nxtfood

Categories: News

Tags:

Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree

Vida Ventures

SAN DIEGO–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced that it has been named to the prestigious 2025 Endpoints 11 list. The Endpoints 11 annually recognizes the most promising private biotech companies in the world driving innovation and shaping the future of the industry.

“We are thrilled to receive this recognition after just one year of officially launching the company,” said Dr. Ken Song, Chairman, President, and Chief Executive Officer of Candid. “We believe T-cell engagers represent a transformative modality for patients with debilitating inflammatory conditions, and this recognition underscores the progress our team has made advancing potentially first-in-class and best-in-class programs into the clinic.”

Candid is advancing a comprehensive pipeline of T-cell engagers, anchored by cizutamig, a first-in-class and potentially best-in-class BCMA-targeting TCE currently in clinical evaluation across multiple autoimmune indications. In addition, the company is progressing next-generation CD19- and CD20-targeting programs, including CND261 and CND319, alongside a robust discovery engine designed to expand TCE applications across a broad range of autoimmune and inflammatory diseases.

About Candid Therapeutics

Candid Therapeutics is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune and inflammatory diseases through novel T-cell engager (TCE) platforms. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors.

 

Contacts

Arvind Kush
info@candidrx.com

Categories: News

Tags:

Emerald Welcomes Back Cédric Mutz as Partner and Head of Portfolio Performance

Emerald

Zurich, Switzerland – Emerald Technology Ventures, a global leader in climate-tech venture capital, has announced the appointment of Cédric Mutz as Partner and Head of Portfolio Performance, marking his return to the firm at a pivotal stage in its growth.

Cédric is a seasoned professional with extensive experience in venture capital, corporate finance, and entrepreneurship. Having previously worked at Emerald early in his career, he rejoins the firm after holding senior positions in industry and M&A advisory.

In his new role, Cédric will be responsible for overseeing portfolio performance across Emerald’s funds, supporting founders and management teams. His appointment comes as Emerald has surpassed €1 billion in assets under management and advisory and expanded its suite of funds targeting climate technologies.

“Returning to Emerald feels both natural and energizing,” said Cédric Mutz. “The firm is at an exciting inflection point, with new funds, new mandates, and a growing international footprint. I look forward to helping our portfolio companies scale their impact while delivering strong performance for our investors.”

Emerald Managing Partner Gina Domanig welcomed the appointment, stating:

“We are delighted to have Cédric back at Emerald. He brings a unique combination of investment expertise, operational know-how, and international perspective. His leadership will be instrumental in ensuring the success of our portfolio companies and accelerating the commercialization of sustainable industrial innovation.”

Cédric’s appointment reinforces Emerald’s commitment to driving portfolio success through senior leadership. The enhanced management team also reflects Emerald’s rapid growth and its leading position in the expanding climate tech sector. With this team expansion, Emerald continues to evolve, staying well positioned as a trusted partner for corporates and startups worldwide.


Find out more about Emerald’s growth:

25 Years of Emerald: A Journey of Grit, Trust and Growth

Veralto Commits €20M to Emerald’s New Fund to Accelerate Water Innovation Solutions

How to Pick Winners for a Climate Tech Portfolio

About Emerald Technology Ventures

Emerald is a globally recognized venture capital firm, founded in 2000, that manages and advises assets of over €1 billion from its offices in Zurich, Toronto and Singapore. The firm invests in start-ups that tackle big challenges in climate change and sustainability, with four current funds, hundreds of venture transactions and five third-party investment mandates, including loan guarantees to over 100 start-ups.

This is Emerald.

Bold Ideas. Bright Future.  www.emerald.vc

CONTACT FOR EMERALD:

info@emerald.vc

Categories: People

Tags: